Metformin and Its Immune-Mediated Effects in Various Diseases

Int J Mol Sci. 2023 Jan 1;24(1):755. doi: 10.3390/ijms24010755.

Abstract

Metformin has been a long-standing prescribed drug for treatment of type 2 diabetes (T2D) and its beneficial effects on virus infection, autoimmune diseases, aging and cancers are also recognized. Metformin modulates the differentiation and activation of various immune-mediated cells such as CD4+ and CD+8 T cells. The activation of adenosine 5'-monophosphate-activated protein kinase (AMPK) and mammalian target of rapamycin complex 1 (mTORC1) pathway may be involved in this process. Recent studies using Extracellular Flux Analyzer demonstrated that metformin alters the activities of glycolysis, oxidative phosphorylation (OXPHOS), lipid oxidation, and glutaminolysis, which tightly link to the modulation of cytokine production in CD4+ and CD+8 T cells in various disease states, such as virus infection, autoimmune diseases, aging and cancers.

Keywords: AMPK; CD8 T cells; OXPHOS; aging; autoimmune disease; cancer; mTORC.

Publication types

  • Review

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Mechanistic Target of Rapamycin Complex 1
  • Metformin* / pharmacology
  • Metformin* / therapeutic use
  • Neoplasms* / drug therapy
  • Protein Kinases

Substances

  • Metformin
  • Protein Kinases
  • Mechanistic Target of Rapamycin Complex 1
  • AMP-Activated Protein Kinases